New stock news | China Medical Technology plans to list on Hong Kong IPO. The China Securities Regulatory Commission requires supplementary disclosure on changes in the business scope of its subsidiary companies, etc.

On May 15th, the China Securities Regulatory Commission announced the requirements for supplemental materials for overseas issuance and listing applications to be disclosed (May 11th, 2026 to May 15th, 2026). Among them, the CSRC required Guoyi Medical Technology to provide additional information on changes in the business scope of its subsidiaries. According to the disclosure by the Hong Kong Stock Exchange on January 21st, Anhui Zhongji Guoyi Medical Technology Co., Ltd. (referred to as "Guoyi Technology") submitted an application for listing on the main board of the Hong Kong Stock Exchange, with Haitong International Capital Limited as its sole sponsor. The CSRC requested Guoyi Medical Technology to provide clarification on the following matters, and to have lawyers verify and provide clear legal opinions: 1. Please provide additional information on the company's websites, apps, mini-programs, etc., including the scale of user information collected and stored, data collection and use, whether personal user information is provided to third parties, and arrangements or measures for personal information protection and data security before and after listing. 2. Please provide additional information on changes in the business scope of the company's subsidiaries. 3. Please provide clarification on the reasonableness of the entry prices for new shareholders in the company in the last 12 months, the reasons for any differences in these entry prices, and provide a conclusive opinion on whether there is any transfer of benefits. 4. Please provide clarification on the compliance of the company's implemented equity incentive plans, including the specific composition and appointment of personnel, the existence of any relationships between participating individuals and other shareholders, directors, supervisors, or senior management of the issuer, fairness of prices, agreement provisions, decision-making procedures, and operational norms, and provide a conclusive opinion on legality, compliance, and any potential transfer of benefits. 5. Please provide clarification on whether the shares held by shareholders participating in the "full circulation" this time are subject to pledges, freezes, or other defects in rights. According to the prospectus, Guoyi Medical Technology is the leader in the third-party SPD solution market in China. According to a Frost & Sullivan report, based on 2024 revenue, Guoyi Technology is the largest third-party SPD solution provider in China, with a market share of 29.2%. According to the same report, the company is also the first third-party SPD solution provider in China. The prospectus mentions that SPD refers to supply, processing, and distribution, which is an innovative supply chain model aimed at optimizing the supply and management of medical supplies to hospitals. This model is recognized for its flexibility and adaptability, typically covering (i) hospital procurement and supplier management of medical supplies, (ii) handling and circulation management of medical supplies in hospital central warehouses, and (iii) distribution and issuance management of medical supplies to various departments within the hospital. Traditional hospital medical supply chain models heavily rely on manual operations and decentralized management, with paper records, limited information sharing, and lack of real-time visualization of inventory and procurement.